RAPT Therapeutics, Inc. Common Stock
RAPTRAPT Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and inflammatory diseases. Leveraging its expertise in immunology and small-molecule drug discovery, RAPT aims to modulate immune cell activity to enhance treatment outcomes.
Company News
The food allergy market is expected to grow significantly by 2034, driven by emerging therapies, increased diagnoses, and rising treatment costs. The market was valued at USD 3 billion in 2024, with the US accounting for approximately 79% of the total market.
Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival b...
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 2% on Thursday. Shares of Rivian Automotive, Inc. (NASDAQ: RIVN) fell sharply in today’s pre-market trading after the company reported a wider-than-expected loss for its fourth quarter and announced plans to reduce its salaried workforce by around 1...
RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation drug.
The company reported great results from an early-stage study of its experimental atopic dermatitis drug.
